Sage Capital Advisors llc boosted its holdings in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 0.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 63,297 shares of the biopharmaceutical company’s stock after acquiring an additional 471 shares during the quarter. Bristol-Myers Squibb comprises 2.6% of Sage Capital Advisors llc’s holdings, making the stock its 5th largest holding. Sage Capital Advisors llc’s holdings in Bristol-Myers Squibb were worth $4,063,000 as of its most recent SEC filing.
A number of other hedge funds have also bought and sold shares of BMY. BlackRock Inc. lifted its holdings in Bristol-Myers Squibb by 6.7% during the 2nd quarter. BlackRock Inc. now owns 114,798,394 shares of the biopharmaceutical company’s stock worth $5,206,108,000 after buying an additional 7,178,698 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Bristol-Myers Squibb by 42.7% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 12,749,545 shares of the biopharmaceutical company’s stock valued at $578,192,000 after acquiring an additional 3,816,247 shares during the last quarter. Nuveen Asset Management LLC increased its holdings in shares of Bristol-Myers Squibb by 14,860.1% in the 2nd quarter. Nuveen Asset Management LLC now owns 9,395,120 shares of the biopharmaceutical company’s stock valued at $426,069,000 after acquiring an additional 9,332,319 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. increased its holdings in shares of Bristol-Myers Squibb by 1.9% in the 3rd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 7,386,695 shares of the biopharmaceutical company’s stock valued at $374,579,000 after acquiring an additional 134,804 shares during the last quarter. Finally, UBS Asset Management Americas Inc. increased its holdings in shares of Bristol-Myers Squibb by 9.2% in the 2nd quarter. UBS Asset Management Americas Inc. now owns 6,452,667 shares of the biopharmaceutical company’s stock valued at $292,628,000 after acquiring an additional 542,204 shares during the last quarter. 83.02% of the stock is owned by institutional investors.
A number of research analysts have recently commented on the company. Morgan Stanley assumed coverage on Bristol-Myers Squibb in a report on Friday, November 22nd. They issued an “equal weight” rating and a $60.00 price objective on the stock. Gabelli began coverage on Bristol-Myers Squibb in a report on Wednesday, November 27th. They issued a “buy” rating on the stock. Argus upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $80.00 price target on the stock in a research note on Friday, December 13th. Bank of America began coverage on Bristol-Myers Squibb in a research note on Wednesday, October 16th. They set a “buy” rating and a $60.00 price target on the stock. Finally, TheStreet raised Bristol-Myers Squibb from a “c+” rating to a “b-” rating in a research report on Wednesday, September 18th. One analyst has rated the stock with a sell rating, three have issued a hold rating and thirteen have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $61.69.
Shares of NYSE BMY traded up $0.10 during midday trading on Thursday, reaching $66.68. 3,255,733 shares of the company were exchanged, compared to its average volume of 12,465,342. The company has a current ratio of 3.83, a quick ratio of 3.72 and a debt-to-equity ratio of 1.37. Bristol-Myers Squibb Co has a 1 year low of $42.48 and a 1 year high of $67.09. The stock has a fifty day simple moving average of $62.52 and a 200 day simple moving average of $53.03. The stock has a market cap of $108.25 billion, a P/E ratio of 16.75, a PEG ratio of 0.85 and a beta of 0.73.
Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported $1.17 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.06 by $0.11. Bristol-Myers Squibb had a return on equity of 45.49% and a net margin of 23.53%. The firm had revenue of $6.01 billion during the quarter, compared to the consensus estimate of $5.89 billion. During the same period in the prior year, the business earned $1.09 EPS. The firm’s revenue was up 5.6% compared to the same quarter last year. As a group, analysts forecast that Bristol-Myers Squibb Co will post 4.47 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Monday, February 3rd. Shareholders of record on Friday, January 3rd will be paid a $0.45 dividend. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.41. This represents a $1.80 annualized dividend and a dividend yield of 2.70%. The ex-dividend date is Thursday, January 2nd. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 45.23%.
In related news, SVP John E. Elicker sold 15,000 shares of the stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $56.66, for a total transaction of $849,900.00. Following the completion of the sale, the senior vice president now directly owns 74,471 shares of the company’s stock, valued at $4,219,526.86. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Louis S. Schmukler sold 25,000 shares of the stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $56.56, for a total value of $1,414,000.00. Following the sale, the insider now directly owns 31,963 shares of the company’s stock, valued at $1,807,827.28. The disclosure for this sale can be found here. Insiders own 0.13% of the company’s stock.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
See Also: Analyst Ratings Trading
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.